利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.025 秒)

    Treatment of Obesity or Diabetes with Bile Acid Sequestrants
    1.
    发明申请
    Treatment of Obesity or Diabetes with Bile Acid Sequestrants 审中-公开
    用胆汁酸螯合剂治疗肥胖或糖尿病

    公开(公告)号：US20110152204A1

    公开(公告)日：2011-06-23

    申请号：US12969388

    申请日：2010-12-15

    申请人： Bronislava GEDULIN ,  Howard E. Greene, JR.

    发明人： Bronislava GEDULIN ,  Howard E. Greene, JR.

    IPC分类号： A61K31/56 ,  A61K31/09 ,  A61K31/14 ,  A61K31/131 ,  A61K31/132 ,  A61K31/20 ,  A61K31/155 ,  A61P3/10 ,  A61P3/04

    CPC分类号： A61K31/155 ,  A61K31/74 ,  A61K31/785

    摘要： Provided herein are methods of treating obesity and diabetes with labile bile acid sequestrants. An effective amount of a labile bile acid sequestrant may be orally administered to an obese or diabetic individual. A labile bile acid sequestrant provided herein may have a low affinity in the colon or rectum of a human for at least one bile acid or bile acid mimic that stimulates L-cells. A labile bile acid sequestrant may be a non-systemic labile bile acid sequestrant.

    摘要翻译： 本文提供了用不稳定的胆汁酸多价螯合剂治疗肥胖症和糖尿病的方法。 有效量的不稳定的胆汁酸螯合剂可以口服施用于肥胖或糖尿病个体。 本文提供的不稳定胆汁酸多价螯合剂可以在至少一种刺激L细胞的胆汁酸或胆汁酸模拟物的人结肠或直肠中具有低亲和力。 不稳定的胆汁酸螯合剂可能是非系统不稳定的胆汁酸螯合剂。

    Methods and Apparatus for Treating Obesity and Diabetes
    4.
    发明申请
    Methods and Apparatus for Treating Obesity and Diabetes 审中-公开
    治疗肥胖和糖尿病的方法和手段

    公开(公告)号：US20130090590A1

    公开(公告)日：2013-04-11

    申请号：US13689577

    申请日：2012-11-29

    申请人： Satiogen Pharmaceuticals, Inc.

    发明人： Andrew A. YOUNG ,  Bronislava GEDULIN ,  Howard E. GREENE ,  Robert AYLING ,  Matthew YUREK

    IPC分类号： A61M27/00 ,  A61F2/04

    CPC分类号： A61M27/002 ,  A61F2/04 ,  A61F5/0076

    摘要： Provided herein are methods and shunt devices for treating diabetes and obesity. Methods and shunt devices promote stimulation of secretion of intestinal L-cells and other enteroendocrine cell types. Enteroendocrine secretion is stimulated directly or indirectly by shunting bile and/or pancreatic secretion to segments of the gut more distal than would normally occur. The shunt device may be a flexible catheter that is impervious to such secretions, with a proximal end draining the pancreatic/bile duct, and a distal end residing distally within the lumen of the small or large intestine. The shunt may be inserted with minimally invasive techniques, such as by endoscopy or laparoscopy.

    摘要翻译： 本文提供了用于治疗糖尿病和肥胖症的方法和分流装置。 方法和分流装置促进肠L细胞和其他肠内分泌细胞类型的分泌的刺激。 肠内分泌物通过将胆汁和/或胰腺分泌物直接或间接地刺激到比通常发生的更远的肠道段。 分流装置可以是不透过这种分泌物的柔性导管，其中近端排出胰管/胆管，远端位于小肠或大肠的内腔内。 分流可以用微创技术插入，例如通过内窥镜检查或腹腔镜检查。